2005
DOI: 10.5863/1551-6776-10.4.215
|View full text |Cite
|
Sign up to set email alerts
|

New Antiretroviral Therapies for Pediatric HIV Infection

Abstract: Human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome affect millions of children worldwide. The development of antiretroviral therapy has significantly improved the morbidity and mortality of pediatric patients infected with HIV. Currently, 4 classes of antiretroviral agents exist: nucleoside / nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, and entry inhibitors. A total of 21 single-entity antiretroviral agents a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 47 publications
0
1
0
Order By: Relevance
“…Lopinavir and ritonavir (LPV/r or Kaletra) were approved by FDA in 2000 for treating human immunodeficiency virus-1 (HIV-1) infection [88] . LPV acts against the viral 3CL protease [89] , [90] .…”
Section: Antiviral Therapy For Covid-19mentioning
confidence: 99%
“…Lopinavir and ritonavir (LPV/r or Kaletra) were approved by FDA in 2000 for treating human immunodeficiency virus-1 (HIV-1) infection [88] . LPV acts against the viral 3CL protease [89] , [90] .…”
Section: Antiviral Therapy For Covid-19mentioning
confidence: 99%